Curis Inc. (CRIS): This stock is only starting to move

We’re beginning to see movement in extremely oversold shares of Curis (CRIS), as Roche files a New Drug Application (NDA) filing with the FDA for a Phase II clinical study of Erivedge for patients with idiopathic pulmonary fibrosis (IPF).  Roche and Genentech, according to the latest press release are developing and commercializing under a deal…

Details